Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 86

1.

Mean Platelet Volume Predicts Vascular Access Events in Hemodialysis Patients.

Lano G, Sallée M, Pelletier M, Bataille S, Fraisse M, Berda-Haddad Y, Brunet P, Burtey S.

J Clin Med. 2019 May 4;8(5). pii: E608. doi: 10.3390/jcm8050608.

2.

Comparing health-related quality of life in chronic diseases: the importance of analyzing references.

Maynié-François C, Burtey S.

Nat Rev Dis Primers. 2019 Apr 18;5(1):28. doi: 10.1038/s41572-019-0082-3. No abstract available.

PMID:
31000725
3.

Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease.

Santana Machado T, Cerini C, Burtey S.

Toxins (Basel). 2019 Apr 7;11(4). pii: E209. doi: 10.3390/toxins11040209. Review.

4.

Sudden Onset Nephrotic-Range Proteinuria.

Fromonot J, Marlinge M, Petit C, Burtey S, Guieu R.

Clin Chem. 2019 Apr;65(4):600-601. doi: 10.1373/clinchem.2018.295519. No abstract available.

PMID:
30923065
5.

Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients.

Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F, Vanholder R, Brigant B, Pletinck A, Diouf M, Burtey S, Choukroun G, Massy ZA, Metzinger L; European Uremic Toxin Work Group-EUTox.

Sci Rep. 2019 Mar 14;9(1):4477. doi: 10.1038/s41598-019-41101-8.

6.

Myeloma cast nephropathy: the dusk of high cutoff haemodialysis.

Sallée M, Burtey S.

Lancet Haematol. 2019 Apr;6(4):e174-e176. doi: 10.1016/S2352-3026(19)30044-4. Epub 2019 Mar 11. No abstract available.

PMID:
30872076
7.

Myostatin and Insulin-Like Growth Factor 1 Are Biomarkers of Muscle Strength, Muscle Mass, and Mortality in Patients on Hemodialysis.

Delanaye P, Bataille S, Quinonez K, Buckinx F, Warling X, Krzesinski JM, Pottel H, Burtey S, Bruyère O, Cavalier E.

J Ren Nutr. 2019 Jan 25. pii: S1051-2276(18)30280-2. doi: 10.1053/j.jrn.2018.11.010. [Epub ahead of print]

PMID:
30686748
8.

Endothelium structure and function in kidney health and disease.

Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtey S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec M, Pernin V, Rigothier C, Sallée M, Fremeaux-Bacchi V, Guerrot D, Roumenina LT.

Nat Rev Nephrol. 2019 Feb;15(2):87-108. doi: 10.1038/s41581-018-0098-z. Review.

PMID:
30607032
9.

Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

Daviet F, Rouby F, Poullin P, Moussi-Francès J, Sallée M, Burtey S, Mancini J, Duffaud F, Sabatier R, Pourroy B, Grandvuillemin A, Grange S, Frémeaux-Bacchi V, Coppo P, Micallef J, Jourde-Chiche N.

Br J Clin Pharmacol. 2019 Feb;85(2):403-412. doi: 10.1111/bcp.13808. Epub 2018 Dec 18.

PMID:
30394581
10.

Hemodialysis vascular graft as a focus of persistent Q fever.

Ernest V, Cammilleri S, Amabile P, Fedi M, Burtey S, Von Kotze C, Pelletier M, Moal V, Guedj E, Perron C, Boustani R, Berland Y, Brunet P, Raoult D, Fournier PE, Jourde-Chiche N.

Infection. 2018 Dec;46(6):881-884. doi: 10.1007/s15010-018-1206-5. Epub 2018 Oct 27.

PMID:
30368731
11.

Specialists to the Rescue of Oncologists for the Management of Toxicity Occurring Under Combination of Anticancer Therapies.

Chevalier T, Burtey S, Barlesi F.

J Thorac Oncol. 2018 Nov;13(11):e231-e232. doi: 10.1016/j.jtho.2018.07.003. No abstract available.

PMID:
30368416
12.

Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor-kappa B signaling pathway in human endothelial cells.

Addi T, Poitevin S, McKay N, El Mecherfi KE, Kheroua O, Jourde-Chiche N, de Macedo A, Gondouin B, Cerini C, Brunet P, Dignat-George F, Burtey S, Dou L.

Arch Toxicol. 2019 Jan;93(1):121-136. doi: 10.1007/s00204-018-2328-3. Epub 2018 Oct 15.

PMID:
30324315
13.

Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease.

Addi T, Dou L, Burtey S.

Toxins (Basel). 2018 Oct 12;10(10). pii: E412. doi: 10.3390/toxins10100412. Review.

14.

Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease.

Bonello L, Laine M, Lemesle G, Puymirat E, Dabry T, Thuny F, Paganelli F, Aradi D, Frere C, Burtey S, Sibbing D, Mancini J.

Thromb Haemost. 2018 Oct;118(10):1839-1846. doi: 10.1055/s-0038-1669426. Epub 2018 Sep 20.

PMID:
30235475
15.

Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe.

Coussement J, Maggiore U, Manuel O, Scemla A, López-Medrano F, Nagler EV, Aguado JM, Abramowicz D; European Renal Association-European Dialysis Transplant Association (ERA-EDTA) Developing Education Science and Care for Renal Transplantation in European States (DESCARTES) working group and the European Study Group for Infections in Compromised Hosts (E; COLLABORATORS (IN ALPHABETICAL ORDER) ; European Renal Association-European Dialysis Transplant Association (ERA-EDTA) Developing Education Science and Care for Renal Transplantation in European States (DESCARTES) working group and the European Study Group for Infections in Compromised Hosts (ESGICH) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).

Nephrol Dial Transplant. 2018 Sep 1;33(9):1661-1668. doi: 10.1093/ndt/gfy078.

PMID:
29635410
16.

Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease.

Dou L, Poitevin S, Sallée M, Addi T, Gondouin B, McKay N, Denison MS, Jourde-Chiche N, Duval-Sabatier A, Cerini C, Brunet P, Dignat-George F, Burtey S.

Kidney Int. 2018 Apr;93(4):986-999. doi: 10.1016/j.kint.2017.11.010. Epub 2018 Feb 1.

PMID:
29395338
17.

Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling.

Santana Machado T, Poitevin S, Paul P, McKay N, Jourde-Chiche N, Legris T, Mouly-Bandini A, Dignat-George F, Brunet P, Masereeuw R, Burtey S, Cerini C.

J Am Soc Nephrol. 2018 Mar;29(3):906-918. doi: 10.1681/ASN.2017030361. Epub 2017 Dec 8.

18.

Research and Therapeutic Nihilisms in Chronic Kidney Disease.

Laine M, Burtey S, Puymirat E, Lemesle G, Bonello L.

JACC Cardiovasc Interv. 2017 Nov 27;10(22):2343-2344. doi: 10.1016/j.jcin.2017.08.038. No abstract available.

19.

[Uro- and nephrotoxic effects of drugs of abuse: Literature review and pharmaco-epidemiological survey in France and in the Marseille area].

Gully M, Frauger É, Spadari M, Pochard L, Pauly V, Romain F, Gondouin B, Sallée M, Moussi-Frances J, Burtey S, Dussol B, Daniel L, Micallef J, Jourde-Chiche N.

Nephrol Ther. 2017 Nov;13(6):429-438. doi: 10.1016/j.nephro.2017.01.024. Epub 2017 Sep 27. Review. French.

PMID:
28958905
20.

Towards Addressing the Body Electrolyte Environment via Sweat Analysis:Pilocarpine Iontophoresis Supports Assessment of Plasma Potassium Concentration.

Vairo D, Bruzzese L, Marlinge M, Fuster L, Adjriou N, Kipson N, Brunet P, Cautela J, Jammes Y, Mottola G, Burtey S, Ruf J, Guieu R, Fenouillet E.

Sci Rep. 2017 Sep 18;7(1):11801. doi: 10.1038/s41598-017-12211-y.

Supplemental Content

Loading ...
Support Center